SEC Form SC 13G filed by Ardelyx Inc.

7/10/23 2:36:44 PM ET

Biotechnology: Pharmaceutical Preparations

Health Care

Get the next $ARDX alert in real time by email

SC 13G 1 Ardelyx_Inc.txt UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 INITIAL FILING ARDELYX INC (NAME OF ISSUER) COMMON STOCK (TITLE OF CLASS OF SECURITIES) 039697107 (CUSIP NUMBER) 06/30/2023 (DATE OF EVENT WHICH REQUIRES FILING OF THIS STATEMENT) CHECK THE APPROPRIATE BOX TO DESIGNATE THE RULE PURSUANT TO WHICH THIS SCHEDULE IS FILED: (X) RULE 13D-1 (B) ( ) RULE 13D-1 (C) ( ) RULE 13D-1 (D) *THE REMAINDER OF THIS COVER PAGE SHALL BE FILLED OUT FOR A REPORTING PERSON`S INITIAL FILING ON THIS FORM WITH RESPECT TO THE SUBJECT CLASS OF SECURITIES, AND FOR ANY SUBSEQUENT AMENDMENT CONTAINING INFORMATION WHICH WOULD ALTER THE DISCLOSURES PROVIDED IN A PRIOR COVER PAGE. THE INFORMATION REQUIRED IN THE REMAINDER OF THIS COVER PAGE SHALL NOT BE DEEMED TO BE "FILED" FOR THE PURPOSE OF SECTION 18 OF THE SECURITIES EXCHANGE ACT OF 1934 ("ACT") OR OTHERWISE SUBJECT TO THE LIABILITIES OF THAT SECTION OF THE ACT BUT SHALL BE SUBJECT TO ALL OTHER PROVISIONS OF THE ACT (HOWEVER, SEE THE NOTES). CUSIP NO: 039697107 13G Page 2 of 7 Pages 1. NAME OF REPORTING PERSON: STATE STREET CORPORATION I.R.S. IDENTIFICATION NO. OF THE ABOVE PERSON: 04-2456637 2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP NOT APPLICABLE 3. SEC USE ONLY 4. CITIZENSHIP OR PLACE OF ORGANIZATION BOSTON, MASSACHUSETTS 5. SOLE VOTING POWER 0 SHARES 6. SHARED VOTING POWER 22,099,414 7. SOLE DISPOSITIVE POWER 0 SHARES 8. SHARED DISPOSITIVE POWER 22,437,564 9. AGGREGATED AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 22,437,564 10. CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES NOT APPLICABLE 11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9 10.46% 12. TYPE OF REPORTING PERSON HC CUSIP NO: 039697107 13G Page 3 of 7 Pages 1. NAME OF REPORTING PERSON: SSGA FUNDS MANAGEMENT, INC. I.R.S. IDENTIFICATION NO. OF THE ABOVE PERSON: 04-3555193 2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP NOT APPLICABLE 3. SEC USE ONLY 4. CITIZENSHIP OR PLACE OF ORGANIZATION BOSTON, MASSACHUSETTS 5. SOLE VOTING POWER 0 SHARES 6. SHARED VOTING POWER 18,106,871 7. SOLE DISPOSITIVE POWER 0 SHARES 8. SHARED DISPOSITIVE POWER 18,149,071 9. AGGREGATED AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 18,149,071 10. CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES NOT APPLICABLE 11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9 8.46% 12. TYPE OF REPORTING PERSON IA CUSIP NO: 039697107 13G Page 4 of 7 Pages ITEM 1. (A) NAME OF ISSUER ARDELYX INC (B) ADDRESS OF ISSUER`S PRINCIPAL EXECUTIVE OFFICES 34175 ARDENWOOD BLVD SUITE 200 FREMONT CA 94555 UNITED STATES ITEM 2. (A) NAME OF PERSON FILING STATE STREET CORPORATION SSGA FUNDS MANAGEMENT, INC. (B) ADDRESS OF PRINCIPAL BUSINESS OFFICE OR, IF NONE, RESIDENCE STATE STREET FINANCIAL CENTER 1 CONGRESS STREET, SUITE 1 BOSTON, MA 02114-2016 (FOR ALL REPORTING PERSONS) (C) CITIZENSHIP: SEE ITEM 4 (CITIZENSHIP OR PLACE OF ORGANIZATION) OF COVER PAGES (D) TITLE OF CLASS OF SECURITIES COMMON STOCK (E) CUSIP NUMBER: 039697107 ITEM 3. IF THIS STATEMENT IS FILED PURSUANT TO RULE 13D-1(B), OR 13D-2(B) OR (C), CHECK WHETHER THE PERSON FILING IS A: SEE ITEM 12(TYPE OF REPORTING PERSON) OF THE COVER PAGE FOR EACH REPORTING PERSON AND THE TABLE BELOW, WHICH EXPLAINS THE MEANING OF THE TWO LETTER SYMBOLS APPEARING IN ITEM 12 OF THE COVER PAGES. SYMBOL CATEGORY BK BANK AS DEFINED IN SECTION 3(A) (6) OF THE ACT. IC INSURANCE COMPANY AS DEFINED IN SECTION 3 (A) (19) OF THE ACT IC INVESTMENT COMPANY REGISTERED UNDER SECTION 8 OF THE INVESTMENT COMPANY ACT OF 1940. IA AN INVESTMENT ADVISOR IN ACCORDANCE WITH RULE 13D-1(B) (1) (II) (E). EP AN EMPLOYEE BENEFIT PLAN OR ENDOWMENT FUND IN ACCORDANCE WITH RULE 13D-1(B) (1) (II) (F) . HC A PARENT HOLDING COMPANY OR CONTROL PERSON IN ACCORDANCE WITH RULE 13D-1(B)(1)(II) (G). SA A SAVINGS ASSOCIATIONS AS DEFINED IN SECTION 3(B) OF THE FEDERAL DEPOSIT INSURANCE ACT (12 U.S.C. 1813). CP A CHURCH PLAN THAT IS EXCLUDED FROM THE DEFINITION OF AN INVESTMENT COMPANY UNDER SECTION 3(C)(14) OF THE INVESTMENT COMPANY ACT OF 1940. CUSIP NO:039697107 13G Page 5 of 7 Pages ITEM 4. OWNERSHIP THE INFORMATION SET FORTH IN ROWS 5 THROUGH 11 OF THE COVER PAGE HERETO FOR EACH OF THE REPORTING PERSONS IS INCORPORATED HEREIN BY REFERENCE. ITEM 5. OWNERSHIP OF FIVE PERCENT OR LESS OF CLASS NOT APPLICABLE ITEM 6. OWNERSHIP OF MORE THAN FIVE PERCENT ON BEHALF OF ANOTHER PERSON NOT APPLICABLE ITEM 7. IDENTIFICATION AND CLASSIFICATION OF THE SUBSIDIARY WHICH ACQUIRED THE SECURITY BEING REPORTED ON BY THE PARENT HOLDING COMPANY OR CONTROL PERSON SEE EXHIBIT 1 ATTACHED HERETO ITEM 8. IDENTIFICATION AND CLASSIFICATION OF MEMBERS OF THE GROUP NOT APPLICABLE ITEM 9. NOTICE OF DISSOLUTION OF GROUP NOT APPLICABLE CUSIP NO: 039697107 13G Page 6 of 7 Pages ITEM 10. CERTIFICATION BY SIGNING BELOW I CERTIFY THAT, TO THE BEST OF MY KNOWLEDGE AND BELIEF, THE SECURITIES REFERRED TO ABOVE WERE ACQUIRED AND ARE HELD IN THE ORDINARY COURSE OF BUSINESS AND WERE NOT ACQUIRED AND ARE NOT HELD FOR THE PURPOSE OR WITH THE EFFECT OF CHANGING OR INFLUENCING THE CONTROL OF THE ISSUER OF THE SECURITIES AND WERE NOT ACQUIRED AND ARE NOT HELD IN CONNECTION WITH OR AS A PARTICIPANT IN ANY TRANSACTION HAVING THAT PURPOSE OR EFFECT. SIGNATURES AFTER REASONABLE INQUIRY AND TO THE BEST OF HIS KNOWLEDGE AND BELIEF, EACH OF THE UNDERSIGNED CERTIFIES THAT THE INFORMATION SET FORTH IN THIS STATEMENT IS TRUE, COMPLETE AND CORRECT. STATE STREET CORPORATION ELIZABETH SCHAEFER SENIOR VICE PRESIDENT, DEPUTY CONTROLLER SSGA FUNDS MANAGEMENT, INC. BRIAN HARRIS CHIEF COMPLIANCE OFFICER EXHIBIT 1 THE FOLLOWING TABLE LISTS THE IDENTITY AND ITEM 3 CLASSIFICATION OF EACH SUBSIDIARY OF STATE STREET CORPORATION, THE PARENT HOLDING COMPANY, THAT BENEFICIALLY OWNS THE ISSUER`S SECURITIES. PLEASE REFER TO ITEM 3 OF THE ATTACHED SCHEDULE 13G FOR A DESCRIPTION OF EACH OF THE TWO-LETTER SYMBOLS REPRESENTING THE ITEM 3 CLASSIFICATION BELOW. SUBSIDIARY ITEM 3 CLASSIFICATION SSGA FUNDS MANAGEMENT, INC. IA STATE STREET GLOBAL ADVISORS EUROPE LIMITED IA STATE STREET GLOBAL ADVISORS LIMITED IA STATE STREET GLOBAL ADVISORS TRUST COMPANY IA NOTE: ALL OF THE LEGAL ENTITIES ABOVE ARE DIRECT OR INDIRECT SUBSIDIARIES OF STATE STREET CORPORATION. CUSIP NO:039697107 13G Page 7 of 7 Pages JOINT FILING AGREEMENT IN ACCORDANCE WITH RULE 13D-1(K)(1) UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED (THE EXCHANGE ACT), EACH UNDERSIGNED ENTITY (EACH A COMPANY) HEREBY AGREES TO ANY AND ALL JOINT FILINGS REQUIRED TO BE MADE ON THE COMPANY`S BEHALF ON SCHEDULE 13G (INCLUDING AMENDMENTS THERETO) UNDER THE EXCHANGE ACT, WITH RESPECT TO SECURITIES WHICH MAY BE DEEMED TO BE BENEFICIALLY OWNED BY THE COMPANY UNDER THE EXCHANGE ACT, AND THAT THIS AGREEMENT BE INCLUDED AS AN EXHIBIT TO ANY SUCH JOINT FILING. THIS AGREEMENT MAY BE EXECUTED IN ANY NUMBER OF COUNTERPARTS ALL OF WHICH TAKEN TOGETHER SHALL CONSTITUTE ONE AND THE SAME INSTRUMENT. IN WITNESS WHEREOF, EACH COMPANY HEREBY EXECUTES THIS AGREEMENT EFFECTIVE AS OF THE DATE SET FORTH BELOW. STATE STREET CORPORATION ELIZABETH SCHAEFER SENIOR VICE PRESIDENT, DEPUTY CONTROLLER SSGA FUNDS MANAGEMENT, INC. BRIAN HARRIS CHIEF COMPLIANCE OFFICER

Get the next $ARDX alert in real time by email

Recent Analyst Ratings for

$ARDX

Date	Price Target	Rating	Analyst
7/2/2024	$15.00 → $7.00	Overweight → Neutral	Piper Sandler
4/5/2024	$14.00	Outperform	Leerink Partners
12/18/2023	$12.00	Strong Buy	Raymond James
9/7/2023	$9.00	Buy	H.C. Wainwright
8/25/2023	$5.00 → $10.00	Neutral → Overweight	Cantor Fitzgerald
3/3/2023	$3.00 → $6.00	Neutral → Outperform	Wedbush
11/17/2022	$3.00 → $8.00	Neutral → Overweight	Piper Sandler
5/6/2022	$7.00 → $1.00	Overweight → Neutral	Cantor Fitzgerald

More analyst ratings

SEC Form SC 13G filed by Ardelyx Inc.

Chat with this insight

Recent Analyst Ratings for $ARDX

$ARDX Large Ownership Changes

This live feed shows all institutional transactions in real time.

Amendment: SEC Form SC 13G/A filed by Ardelyx Inc.

SEC Form SC 13G/A filed by Ardelyx Inc. (Amendment)

SEC Form SC 13G filed by Ardelyx Inc.

$ARDX FDA approvals

Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

$ARDX SEC Filings

FDA Approval for XPHOZAH issued to ARDELYX INC

FDA Approval for XPHOZAH issued to ARDELYX INC

FDA Approval for XPHOZA™ issued to ARDELYX INC

SEC Form 10-Q filed by Ardelyx Inc.

Ardelyx Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

SEC Form 144 filed by Ardelyx Inc.

$ARDX Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

President & CEO Raab Michael exercised 25,000 shares at a strike of $0.99 and sold $147,740 worth of shares (25,000 units at $5.91) (SEC Form 4)

President & CEO Raab Michael sold $45,075 worth of shares (7,500 units at $6.01), decreasing direct ownership by 0.62% to 1,210,108 units (SEC Form 4)

Chief Development Officer Rosenbaum David P. sold $342,983 worth of shares (49,564 units at $6.92), decreasing direct ownership by 14% to 301,946 units (SEC Form 4)

$ARDX Financials

Live finance-specific insights

Ardelyx Reports Third Quarter 2024 Financial Results and Provides Business Update

Ardelyx to Report Third Quarter 2024 Financial Results on October 31, 2024

Ardelyx Reports Second Quarter 2024 Financial Results and Provides Business Update

$ARDX Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

Ardelyx downgraded by Piper Sandler with a new price target

Leerink Partners initiated coverage on Ardelyx with a new price target

Raymond James initiated coverage on Ardelyx with a new price target

$ARDX Market Insights

Live Market Insights

$ARDX Press Releases

Fastest customizable press release news feed in the world

$ARDX Leadership Updates

Live Leadership Updates

HC Wainwright & Co. Reiterates Buy on Ardelyx, Maintains $10 Price Target

Ardelyx Files Lawsuit Over Medicare Drug Payment Rules, Claims It Will Limit Patient Access To Kidney Disease Treatment

Wedbush Reiterates Outperform on Ardelyx, Maintains $11 Price Target

Ardelyx Reports Third Quarter 2024 Financial Results and Provides Business Update

Ardelyx Presents Results from its IBS in America 2024 Supplemental Survey at the American College of Gastroenterology's (ACG) Annual Meeting

Ardelyx Shares Additional Data Supporting First-In-Class XPHOZAH® (tenapanor) at the American Society of Nephrology's Kidney Week

Ardelyx Appoints Experienced Biopharma Executive, Eric Foster, as Chief Commercial Officer

Ardelyx Appoints Veteran BioPharma Executive, Mike Kelliher, as Executive Vice President, Corporate Development and Strategy

Intellia Therapeutics Names Muna Bhanji, R.Ph., to its Board of Directors

Recent Analyst Ratings for
$ARDX

$ARDX
Large Ownership Changes

$ARDX
FDA approvals

$ARDX
SEC Filings

$ARDX
Insider Trading

$ARDX
Financials

$ARDX
Analyst Ratings

$ARDX
Market Insights

$ARDX
Press Releases

$ARDX
Leadership Updates